Skip to main content

Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission.

Publication ,  Journal Article
Vasu, S; Kohlschmidt, J; Mrózek, K; Eisfeld, A-K; Nicolet, D; Sterling, LJ; Becker, H; Metzeler, KH; Papaioannou, D; Powell, BL; Kolitz, JE ...
Published in: Blood Adv
July 10, 2018

The probability that adult patients with de novo acute myeloid leukemia (AML) receiving intensive chemotherapy in the absence of allogeneic hematopoietic stem cell transplantation (Allo-HCT) in first complete remission (CR1) will be disease-free at 10 years after diagnosis, a long-term surrogate of cure, is unknown. To address this question, we examined 2551 AML patients (1607 aged <60 years, and 944 aged ≥60 years) enrolled in Cancer and Leukemia Group B treatment protocols and the cytogenetics companion protocol 8461 between 1983 and 2004. At 10 years, 267 (16.6%) of patients aged <60 years and 23 (2.4%) of those aged ≥60 years were alive and disease-free. This disease-free AML group consisted predominantly of patients with core-binding factor AML with t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22) and those with a normal karyotype. Occurrences of AML beyond 10 years were infrequent and associated with cytogenetic findings different from those at diagnosis. These data provide evidence that the frequency of long-term cure of AML is low among younger and especially older patients in the absence of Allo-HCT in CR1. In older patients not appropriate for Allo-HCT, these data provide further justification for early use of alternative treatments outside of intensive chemotherapy.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Blood Adv

DOI

EISSN

2473-9537

Publication Date

July 10, 2018

Volume

2

Issue

13

Start / End Page

1645 / 1650

Location

United States

Related Subject Headings

  • Survival Rate
  • Retrospective Studies
  • Middle Aged
  • Male
  • Leukemia, Myeloid, Acute
  • Humans
  • Hematopoietic Stem Cell Transplantation
  • Follow-Up Studies
  • Female
  • Disease-Free Survival
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Vasu, S., Kohlschmidt, J., Mrózek, K., Eisfeld, A.-K., Nicolet, D., Sterling, L. J., … Bloomfield, C. D. (2018). Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission. Blood Adv, 2(13), 1645–1650. https://doi.org/10.1182/bloodadvances.2017015222
Vasu, Sumithira, Jessica Kohlschmidt, Krzysztof Mrózek, Ann-Kathrin Eisfeld, Deedra Nicolet, Lisa J. Sterling, Heiko Becker, et al. “Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission.Blood Adv 2, no. 13 (July 10, 2018): 1645–50. https://doi.org/10.1182/bloodadvances.2017015222.
Vasu S, Kohlschmidt J, Mrózek K, Eisfeld A-K, Nicolet D, Sterling LJ, et al. Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission. Blood Adv. 2018 Jul 10;2(13):1645–50.
Vasu, Sumithira, et al. “Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission.Blood Adv, vol. 2, no. 13, July 2018, pp. 1645–50. Pubmed, doi:10.1182/bloodadvances.2017015222.
Vasu S, Kohlschmidt J, Mrózek K, Eisfeld A-K, Nicolet D, Sterling LJ, Becker H, Metzeler KH, Papaioannou D, Powell BL, Kolitz JE, Moore JO, Baer MR, Roboz GJ, Stone RM, Byrd JC, Carroll AJ, Bloomfield CD. Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission. Blood Adv. 2018 Jul 10;2(13):1645–1650.

Published In

Blood Adv

DOI

EISSN

2473-9537

Publication Date

July 10, 2018

Volume

2

Issue

13

Start / End Page

1645 / 1650

Location

United States

Related Subject Headings

  • Survival Rate
  • Retrospective Studies
  • Middle Aged
  • Male
  • Leukemia, Myeloid, Acute
  • Humans
  • Hematopoietic Stem Cell Transplantation
  • Follow-Up Studies
  • Female
  • Disease-Free Survival